中國生物製藥(01177.HK):謝炳及鄭翔玲以饋贈方式無償向其子謝承潤轉讓21.45%股權
格隆匯10月22日丨中國生物製藥(01177.HK)發佈公告,公司接獲通知,2019年10月22日,謝炳及鄭翔玲(均為公司執行董事及主要股東)分別把其實益擁有的4.5億股及22.5億股公司股份以饋贈方式無償轉讓予其兒子謝承潤。
根據披露,2019年10月22日,Validated Profits Limited(一家由謝炳全資擁有及控制的公司)把其持有的4.5億股公司股份(佔公司已發行股本總額約3.57%)以饋贈方式無償轉讓予 Thousand Eagles Limited(一家由謝承潤全資擁有及控制的公司)。
同日,正大百年集團有限公司(一家由鄭翔玲全資擁有及控制的公司)把其持有的11.25億股公司股份(佔公司已發行股本總額約 8.94%)以饋贈方式無償轉讓予 Thousand Eagles Limited。此外,2019年10月22日,鄭翔玲把其全資擁有及控制的公司 Remarkable Industries Limited 的全部股權以饋贈方式無償轉讓予謝承潤,Remarkable Industries Limited 目前持有11.25億股公司股份(佔公司已發行股本總額約 8.94%)。
謝承潤先生表示,在被動參與媒體或其他單位編制的富豪榜或財富排名時,將盡量避免以個人名義參與該等排名,而會建議以謝炳家族(其成員包括謝炳、鄭翔玲、謝其潤及謝承潤)的名義參與。
公司亦接獲通知,主要股東進行該等股份轉讓是為了完善家族財富的管理與承傳;謝承潤將長線持有相關股份;謝炳會留任公司董事及董事長;謝炳家族各成員將繼續同心同德、竭盡所能,為不斷提升公司核心競爭力及實現企業可持續發展而努力。因此,公司董事會認為,該等股份轉讓將不會對公司的業務運作造成任何重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.